This story has been updated to reflect NeoGenomics' estimate on the valuation of the common stock portion of the deal and include debt the firm has taken on to finance it.


NEW YORK (GenomeWeb) – NeoGenomics today announced it has signed a definitive agreement to acquire cancer molecular diagnostics firm Clarient in a cash and stock deal worth approximately $275 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.